Scientific Article
previous document  unige:29755  next document
add to browser collection
Title

Changes in the sex hormone profile of male patients with moderate-to-severe plaque-type psoriasis under systemic therapy: results of a prospective longitudinal pilot study

Authors
Salgo, Rebekka
Garbaraviciene, Jurate
Beschmann, Heike
Ackermann, Hanns
Ochsendorf, Falk Rudiger
Published in Archives of Dermatological Research. 2011, vol. 303, no. 6, p. 417-424
Abstract Patients with moderate-to-severe plaque-type psoriasis exhibit increased cardiovascular mortality. Recent publications point towards psoriasis-induced insulin resistance as an important pathomechanism driving cardiovascular comorbidity in these patients. As the hormonal status in general and sex hormone-binding globulin (SHBG) in particular serve as sensitive indicators for insulin resistance, we analysed these parameters in the context of a set of multiple additional clinical and laboratory measurements in a cohort of male patients. Of 33 consecutively enrolled male patients receiving continuous systemic therapy for their moderate-to-severe plaque-type psoriasis, 23 male patients for whom all parameters could be collected over a 24-week treatment period were included in this analysis. At baseline, testosterone levels varied between 212 and 660 ng/ml (median: 377.0), and SHBG between 11.9 and 46.0 nmol/l (median: 29.2), thus documenting lack of hypogonadism among these patients. Clinically, 19/23 patients experienced at least a 50% reduction in their PASI under therapy. Using a multivariate regression model to further analyse the sub-group of patients responding to treatment, hs-CRP, PASI, leptin and resistin all improved under effective systemic anti-inflammatory therapy, thus losing their significant influence on SHBG. SHBG performed well as a sensitive biomarker for insulin resistance and systemic inflammation in these patients. Its improvement, as well as the reduction of resistin serum levels, most likely reflects a state of reduced cardiovascular risk in patients undergoing effective continuous systemic therapy. Long-term safety data, generated e.g. from psoriasis registries, are needed to assess whether this effect translates into reduced cardiovascular mortality.
Keywords AdultAgedBiological Markers/*metabolismC-Reactive Protein/metabolismCardiovascular Diseases/*diagnosis/drug therapy/physiopathologyDisease ProgressionFollow-Up StudiesHumansInflammationInsulin ResistanceLeptin/metabolismMaleMiddle AgedPilot ProjectsProspective StudiesPsoriasis/*diagnosis/drug therapy/physiopathologyResistin/*metabolismRiskSex Hormone-Binding Globulin/*metabolismTestosterone/metabolism
Identifiers
PMID: 21660442
Full text
Citation
(ISO format)
BOEHNCKE, Sandra et al. Changes in the sex hormone profile of male patients with moderate-to-severe plaque-type psoriasis under systemic therapy: results of a prospective longitudinal pilot study. In: Archives of Dermatological Research, 2011, vol. 303, n° 6, p. 417-424. https://archive-ouverte.unige.ch/unige:29755

237 hits

0 download

Update

Deposited on : 2013-09-20

Export document
Format :
Citation style :